The Pathogenesis and Prognostic Factors of Lymphoma

NCT06203652 | Recruiting DMC

• 1 other identifier: SHZS-lym-001
• Study Type: observational
• Target: 2,000
• Locations: 1 country
• Sites: 1

Brief Summary

The aim of this study is to describe the clinical and genetic characteristics of Chinese lymphoma patients, and to explore the relationship between those characteristics and phatogenesis.

Conditions

Lymphoma; Hodgkin Lymphoma; Non-hodgkin Lymphoma

Keywords

lymphoma; Hodgkin lymphoma; Non-Hodgkin lymphoma; THRLBCL; DLBCL; MZL; CLL/SLL; MCL; WM

Outcome Measures

Primary Outcomes (1)

• OS

  Overall survival (OS) refers to the time from receiving the first dose to death from any cause

  Baseline up to data cut-off (Up to approximately 20 years)

Secondary Outcomes (1)

• PFS

  Baseline up to data cut-off (Up to approximately 20 years)

Study Arms (1)

All enrolled patients

All patients who are eligible for participation to the study.

Other: Real-world regimen

Interventions

Real-world regimen OTHER

The final personalized management strategy is determined based on current conventional treatment options, physician and patient preferences.The following protocols: chemotherapy, immunochemotherapy,Anti-cd20 monoclonal antibody, BTKi and so on

All enrolled patients

Eligibility Criteria

• Sex: all
• Healthy Volunteers: No
• Age Groups: Child (0-17), Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

Patients with pathological diagnosis of lymphoma from 2007 to 2027 according to 2016 WHO classification.

You may qualify if:

• Patients with pathological diagnosis of lymphoma (including Hodgkin lymphoma and non-Hodgkin lyphoma, eg. THRLBCL, DLBCL, MZL, CLL/SLL...) from 2007 to 2027.
• Patients with complete diagnostic, treatment and follow-up records.
• Fully comprehension and signature of the informed consent form (ICF) for participation.

You may not qualify if:

• Those who refuse to use reliable methods of contraception during pregnancy, lactation or age-appropriate period.
• Severe mental illness.

Sponsors & Collaborators

• Shanghai Zhongshan Hospital: lead

Study Sites (1)

Zhongshan Hospital，Fudan University

Shanghai, Shanghai Municipality, 200032, China

RECRUITING

MeSH Terms

Conditions

Lymphoma; Hodgkin Disease; Lymphoma, Non-Hodgkin

Condition Hierarchy (Ancestors)

Neoplasms by Histologic Type; Neoplasms; Lymphoproliferative Disorders; Lymphatic Diseases; Hemic and Lymphatic Diseases; Immunoproliferative Disorders; Immune System Diseases

Central Study Contacts

Peng Liu, Ph.D

CONTACT

+862164041990; liu.peng@zs-hospital.sh.cn

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: OTHER
• Target Duration: 5 Years
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Chief of Hematology department

Study Record Dates

• First Submitted: January 2, 2024
• First Posted: January 12, 2024
• Study Start: June 5, 2023
• Primary Completion (Estimated): December 31, 2027
• Study Completion (Estimated): December 31, 2028
• Last Updated: January 12, 2024

Record last verified: 2024-01

Locations

CN (1)